Advertisement

Zusammenfassung

Donepezil (Donepezil Hydrochlorid) ist der zweite Acetylcholinesterase-Hemmer, der in Deutschland für die Behandlung von leichten und mittelschweren Demenzen vom Alzheimer-Typ zugelassen worden ist. Es handelt sich um einen Acetylcholinesterase-Hemmer vom Piperidin-Typ, der sich hinsichtlich seiner chemischen Struktur von anderen Cholinesterase-Hemmern wie Tacrin, einer Acridin-Verbindung oder Physostigmin, einem Carbamat, unterscheidet. Die Strukturformel ist der Abb. 12.3.1 zu entnehmen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Galli A, Mori F, Benini L et al. (1994) Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficasy of E2020. Eur J Pharmacol Environ Toxicol Pharmacol 270: 189–193CrossRefGoogle Scholar
  2. Giacobini E, Zhu XD, Williams E, Sherman KA (1996) The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35: 205–211PubMedCrossRefGoogle Scholar
  3. Kawashima K, Sato A, Yoshizawa M et al. (1994) Effects of the centrally acting Cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 350: 523–528PubMedCrossRefGoogle Scholar
  4. Kosasa T, Yamanishi Y, Ogura H et al. (1990) Effects of E2020 on the extracellular level of acethylcholine in the rat cerebral cortex measured by microdialysis without addition of Cholinesterase inhibitor [abstract]. Eur J Pharmacol 183: 1936CrossRefGoogle Scholar
  5. Mihara M, Ohnishi A, Tomono Y et al. (1993) Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 31(5): 223–229PubMedGoogle Scholar
  6. Nochi S, Asakawa N, Sato T (1995) Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4[85,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020). Biol Pharm Bull 18(8): 1145–1147PubMedCrossRefGoogle Scholar
  7. Ohnishi A, Mihara M, Kamakura H et al. (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33: 1086–1091PubMedGoogle Scholar
  8. Rogers SJ, Friedhoff LT (1997) The pharmacokinetic (PK) and pharmacodynamic (PD) profile of donepezil HCL (E2020) following single and multiple oral doses. Clin Pharmacol Ther 61(2): 181Google Scholar
  9. Rogers SL, Friedhoff LT (1998) Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8: 67–75PubMedCrossRefGoogle Scholar
  10. Rogers SL, Yamanishi Y, Yamatsu K (1991) The pharmacology of a piperidine Cholinesterase inhibitor. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 316–320Google Scholar
  11. Rogers SL, Watters EJ, Friedhoff LT (1992) The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 [(R, S,)-1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperadine hydrochloride), a novel inhibitor of acetylcholinesterase (AChE): implications for the use in treatment of Alzheimer’s disease. Neurobiol Aging 13 [Suppl 1]: 125–126Google Scholar
  12. Rogers SL, Friedhoff LT et al. (1996a) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7: 293–303PubMedGoogle Scholar
  13. Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1996b) Donepezil HCL (E2020) improves cognitive and global function in patients with mild to moderately severe Alzheimer’s disease: results of a 15-week phase III study. Poster, 35th Annual Meeting of the ACNP, pp 9–13Google Scholar
  14. Rogers SL, Tiseo PJ, Friedhoff LT (1997) Pharmacokinetics of donepezil HCI (E2020) are unchanged in patients with impaired renal function. Clin Pharmacol Ther 61(2): 217 (PIII-91)Google Scholar
  15. Rogers SL, Farlow MR, Mohs R, Friedhoff LT et al. (1998) A 24-week, doubleblind placebocontrolled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–145PubMedCrossRefGoogle Scholar
  16. Sherman KA (1991) Pharmacodynamics of oral E2020 and tacrine in humane: novel approaches. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 321–328Google Scholar
  17. Sugimoto H, Iimura Y, Yamanishi Y et al. (1992) Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-l-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett 2(8): 871–876CrossRefGoogle Scholar
  18. Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K (1995) Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2yl) methyllpiperidine hydrochloride and related compounds. J Med Chem 38: 4821–4829PubMedCrossRefGoogle Scholar
  19. Tiseo PJ, Rogers SL, Friedhoff LT (1997a) The pharmacokinetic profile of donepezil HCl (E2020) in patients with impaired liver function. Clin Pharm Ther 61 (184): PII–P75Google Scholar
  20. Tiseo PJ, Rogers SL, Friedhoff LT (1997b) Coadministration of donepezil HCL and digoxin produces no pharmacokinetic or pharmacodynamic interactions. Eur Neuropsychopharm 7 [Suppl 2] S252: P.4.024CrossRefGoogle Scholar
  21. Tiseo PJ, Rogers SL, Friedhoff LT (1997c) The pharmacokinetics and pharmacodynamics of (R)-and (S)-warfarin are uneffected by coadministration of donepezil HCL. Eur Neuropsychopharm 7 [Suppl 2]: 251 (P.4.023)CrossRefGoogle Scholar
  22. Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K (1990) Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on Cholinesterase. Comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M (eds) Basic, clinical, and therapeutic aspects of Alzheimer’s and Parkinson’s diseases, vol 2. Plenum Press, New York, pp 409–413CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • U. Hegerl

There are no affiliations available

Personalised recommendations